Baxter’s Failed IVIG For Alzheimer’s May Work In Subpopulations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Looking for signals in subgroup analyses, Baxter finds hint of efficacy in ApoE4 carriers and moderately impaired patients and promises not to walk away from immunoglobulin theory without following up.